Skip to main content
AmigoFish

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

From BioSpace · · 17 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.

Back to BioSpace · Report a problem